Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1422509-99-6

Post Buying Request

1422509-99-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1422509-99-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1422509-99-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,2,5,0 and 9 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1422509-99:
(9*1)+(8*4)+(7*2)+(6*2)+(5*5)+(4*0)+(3*9)+(2*9)+(1*9)=146
146 % 10 = 6
So 1422509-99-6 is a valid CAS Registry Number.

1422509-99-6Relevant articles and documents

Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species

Yang, Wu,Wang, Yufeng,Lai, Amy,Clark, Charles G.,Corte, James R.,Fang, Tianan,Gilligan, Paul J.,Jeon, Yoon,Pabbisetty, Kumar B.,Rampulla, Richard A.,Mathur, Arvind,Kaspady, Mahammed,Neithnadka, Premsai Rai,Arumugam, Arunachalam,Raju, Sivashankaran,Rossi, Karen A.,Myers, Joseph E.,Sheriff, Steven,Lou, Zhen,Zheng, Joanna J.,Chacko, Silvi A.,Bozarth, Jeffrey M.,Wu, Yiming,Crain, Earl J.,Wong, Pancras C.,Seiffert, Dietmar A.,Luettgen, Joseph M.,Lam, Patrick Y. S.,Wexler, Ruth R.,Ewing, William R.

, p. 7226 - 7242 (2020/09/11)

Oral factor XIa (FXIa) inhibitors may provide a promising new antithrombotic therapy with an improved benefit to bleeding risk profile over existing antithrombotic agents. Herein, we report application of a previously disclosed cyclic carbamate P1 linker which provided improved oral bioavailability in the imidazole-based 13-membered macrocycle to the 12-membered macrocycle. This resulted in identification of compound 4 with desired FXIa inhibitory potency and good oral bioavailability but high in vivo clearance. Further structure-activity relationship (SAR) studies of heterocyclic core modifications to replace the imidazole core as well as various linkers to the P1 group led to the discovery of compound 6f, a potent FXIa inhibitor with selectivity against most of the relevant serine proteases. Compound 6f also demonstrated excellent pharmacokinetics (PK) profile (high oral bioavailability and low clearance) in multiple preclinical species. Compound 6f achieved robust antithrombotic efficacy in a rabbit efficacy model at doses which preserved hemostasis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1422509-99-6